This company is no longer active
Sesen Bio Balance Sheet Health
Financial Health criteria checks 6/6
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$166.92m |
Equity | US$158.19m |
Total liabilities | US$30.98m |
Total assets | US$189.17m |
Recent financial health updates
We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12Sesen Bio: Binary Event Approaching
Jun 13Sesen Bio inks global supply partnership with Qilu Pharmaceutical
Jun 02Sesen Bio EPS misses by $0.27
May 10Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
May 07News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Sesen announces positive FDA meeting for vicineum's marketing application
Feb 01Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio/Qilu Pharma's Vicineum IND application accepted for review in China
Jan 13Sesen Bio files US application for its Vicineum in bladder cancer
Dec 21Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21Sesen Bio: A Look At Vicineum's Potential
Nov 29Sesen Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 09Financial Position Analysis
Short Term Liabilities: SESN's short term assets ($189.1M) exceed its short term liabilities ($31.0M).
Long Term Liabilities: SESN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SESN is debt free.
Reducing Debt: SESN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SESN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SESN is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 14.8% per year.